Citations

Clear

4564 citation(s) found for "Yu, Virginia".

Abstract WP284: Recurrent stroke in patients with incident cryptogenic stroke and underlying malignancy: A secondary analysis of the CASPR study
Eklund, Kelsey , Bowman, Anna, Coevering, Russell Van, Penckofer, Mary , Kerrigan, Deborah , Nour, Hassan Aboul , Yaghi, Shadi, Sathya, Anvitha , Alvi, Muhammad , Herpich, Franziska , Shahrivari, Mahan, Zha, Alicia , Farooqui, Mudassir, Rothstein, Aaron , Brown, Samantha , Qdais, Ahmad Abu, Nedelcu, Simona, Thon, Jesse , Omran, Setareh Salehi , Brown, Samantha J , Aboul-Nour, Hassan , Siegler, James E. , Chen, Lucia , Nahab, Fadi B , Yaghi, Shadi , Khasiyev, Farid , Lineback, Christina , Culbertson, Collin J , Sharma, Richa , Jillella, Dinesh , Aziz, Yasmin , Elangovan, Cheran , Farooqui, Mudassir , Khan, Farhan , Brorson, James R. , Liebeskind, David S. , Nedelcu, Simona , Nguyen, Thanh N.

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.wp284 Get It

Introduction: Malignancy represents an important subgroup of embolic stroke of undetermined source (ESUS). We aim to compare infarct features, potential embolic sources, and long-term outcomes in ESUS patients with and without malignancy. Methods: In this pre-specified secondary analysis of the Cardiac Abnormalities in Stroke Prevention and Recurrence (CASPR) retrospective cohort study, active cancers were identified by site investigators and adjudicated as malignant if they were non-squamous or non-basal cell skin cancers. We compared the prevalence of various potential embolic sources (e.g., patent foramen ovale, left ventricular dysfunction, post-stroke atrial fibrillation) among patients with and without malignancy. The risk of recurrent stroke, major bleeding, or death was evaluated using adjusted Cox proportional hazards models, accounting for age, sex, vascular risk factors, competing potential embolic sources, and initial treatment with anticoagulation versus non-anticoagulant (e.g., antiplatelet) regimen. Results: Of the 2201 patients followed over a median of 564 days, 236 (10.7%) were diagnosed with cancer at the time of stroke. Patients with malignancy were older, more frequently hypertensive and did not differ with regards to prevalence of specific infarct patterns or potential cardiac embolic sources. No difference was observed in the composite outcome of recurrent stroke, major bleeding, or death (adjusted HR 1.02, 95% CI, 0.71-1.46). Age (adjusted HR per year 1.02, 95% CI, 1.01-1.03), baseline stroke severity (adjusted HR 1.03 per NIHSS point, 95% CI, 1.01-1.05), prior stroke (adjusted HR 1.68, 95% CI, 1.38-2.05), and multi-territorial infarct pattern (adjusted HR 1.67, 95% CI, 1.33-2.08) were significantly associated with this composite outcome, but anticoagulation was not. There was a nominally lower rate of major bleeding with malignancy (adjusted HR 0.45, 95% CI, 0.19-1.04), a significantly higher rate of death (adjusted HR 1.58, 95% CI, 1.09-2.30), but no significant difference in recurrent ischemic stroke (p=0.31). Conclusions: Patients with malignancy and ESUS had higher mortality but did not differ in recurrent stroke risk or major bleeding when compared to patients without malignancy. Anticoagulation was not independently associated with better outcomes. Further analysis of infarct topology and risk factors may better identify patients for whom anticoagulation may benefit.
Meta‐analysis of randomized controlled trials of external‐beam radiation versus transarterial chemoembolization for hepatocellular carcinoma
Kuehnle, Ryan A. , Ludmir, Ethan B. , Escorcia, Freddy E. , Shrestha, S., Sanford, Nina N. , Court, Colin M. , Ryckman, Jeffrey M. , Lehrer, Eric J. , Gelfond, Jonathan, Newman, Neil B., Ludmir, Ethan B , Sanford, Nina , Court, Colin M , Jethwa, Krishan , Tchelebi, Leila T. , Arora, Sukeshi Patel , Gelfond, Jonathan, Jethwa, Krishan R. , Newman, Neil B.

Mayo Clinic

Cancer | January 30, 2025 | Volume: 131 | Issue: 3 | Pages: No page available

10.1002/cncr.35720 | PMID 39887736 Get It

AbstractBackgroundExternal‐beam radiation (EBRT) is a noninvasive therapeutic alternative to transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). The objective of this study was to conduct a systematic review and meta‐analysis of prospective randomized clinical trials to assess the clinical efficacy of EBRT versus TACE for HCC as either a definitive monotherapy or as a bridge to transplantation/surgery.MethodsA systematic review and meta‐analysis were performed to include prospective randomized trials comparing EBRT versus TACE. Data was analyzed with random and fixed‐effects models. The inconsistency index (I2) was chosen to assess heterogeneity. Three publications were included with a total of 142 patients. Outcomes included local control (LC), overall survival (OS), progression‐free survival (PFS), and occurrences of grade ≥3 toxicity. Comparisons are reported as hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs).ResultsThere were three randomized trials that met inclusion criteria. The EBRT was delivered in three to 15 fractions with a total dose between 30 and 75 gray(Gy). EBRT was associated with significantly improved LC (HR, 0.16; 95% CI, 0.08–0.34; I2 = 0%) and PFS (HR, 0.37; 95% CI, 0.23–0.60; I2, 0%) compared with TACE. There was no significant difference between EBRT and TACE in OS (RR, 0.79; 95% CI, 0.51–1.22; I2 = 0%) or grade ≥3 toxicity (RR, 0.86; 95% CI, 0.31–2.37; I2 = 57%). None of the analyses had statistically significant heterogeneity.ConclusionsCompared with TACE, EBRT yields superior LC and PFS without providing a survival benefit in early and intermediate stage HCC. Additional larger prospective randomized controlled trials should be conducted to further investigate differences in clinical outcomes amongst patients with more advanced disease.
646. Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex
Vemula, Raaga, Mammadova, Mehriban, Wadle, Carly , Muscarella, Anahit, Cimino, Christo , Zeuli, John D. , Howard, Catessa, Butt, Saira , Ong, Aaron, Kaip, Emily A, Tupayachi-Ortiz, Maria G., Fiske, Christina T. , Judd, Chloe, Caniff, Kaylee E , Rybak, Michael J. , Musawa, Mohammed Al , Mejía-Chew, Carlos , Hamad, Yasir , Cohen, Keira A. , Judd, Chloe

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.211 Get It

Abstract Background Mycobacterium abscessus complex (MABC) is a difficult-to-treat infection due to antibiotic resistance. Our study aimed to assess omadacycline’s (OMC) clinical and microbiological outcomes for the treatment of pulmonary MABC. Methods A retrospective study was carried out across 12 US medical institutions from 1/2018-4/2023 to examine the clinical outcomes, and tolerability of OMC treatment for pulmonary MABC. Patients aged ≥ 18 years who were treated with OMC for ≥ 3 months were included. The primary outcome was clinical success at 3, 6, and 12 months. The secondary outcomes were sputum culture conversion rate, adverse effects, and clinical success by subspecies and macrolide susceptibility. Results Thirty-five patients were included in this analysis. Most patients were female (74.3%) and Caucasian (74.3%), with a median (IQR) age of 61 years (51–70). Subspeciation was performed for 22 isolates with predominant M. abscessus subspecies (77.3%). Moreover, coinfection with other NTM species was present in 28.6% of cases where Mycobacterium avium complex was present in 8 cultures. Sixty-eight percent of the MABC isolates were confirmed to be macrolide resistance; half (12/24, 50.0%) were evident by the presence of functional erm gene, while the other half by antimicrobial susceptibility (Table 3). Of the remaining isolates, 14% were macrolide-susceptible, while no information was reported in 17%. The median (IQR) treatment duration of OMC was 8 months (3.9 – 15.7). The most commonly co-administered antibiotics were intravenous amikacin, imipenem/cilastatin, inhaled amikacin and clofazimine with the same percentage (42.9%) (Table 1). Overall, MABC clinical success was observed in 71.4%, 89.7%, and 90.9% in 3-, 6- and 12 months, respectively (Table 3). Adverse effects reported in 34.3%. The most common side effects were gastrointestinal intolerance (25.7%) and hepatoxicity (11.4%), which led to drug discontinuation in 22.9%. Conclusion OMC treatment showed clinical success in > 70% of patients with pulmonary MABC including patients with macrolide resistant strains for more than 3 months. However, larger studies are needed to validate the outcomes beyond 12 months. Disclosures Kaylee E. Caniff, PharmD, BCIDP, T2Biosystems: Honoraria Michael J. Rybak, PharmD, PhD, MPH, Abbvie, Melinta, Sionogi, Merck, T2Biosystems: Advisor/Consultant|Abbvie, Melinta, Sionogi, Merck, T2Biosystems: Grant/Research Support|Abbvie, Melinta, Sionogi, Merck, T2Biosystems: Speaker
P-1869. Utilizing Large Language Models for Enhanced Decision Support in Travel Medicine Clinic: our experience at Mayo Clinic
Akhtar, Haris , Anantraman, Vish, Ammar, Muhammad, Gottweis, Juro, O’Horo, John C. , Anantraman, Vish, Ammar, Muhammad, Challener, Douglas W.

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.2030 Get It

Abstract Background The integration of Generative AI (GAI) into healthcare systems is increasingly recognized for its potential to transform patient management. The primary aim of this research was to evaluate and quantify the performance of large language models (LLMs) in generating actionable travel medicine advice. Architectural design of the Travel Clinic LLM project. Four phases of Discovery, Design, Evaluation, and Implementation/Deployment. Methods This study utilized two iterative phases of evaluation. In the initial phase, LLMs were prompted with detailed clinical scenarios including demographic data, medical and immunization histories, and specific travel plans. These prompts were designed to mimic typical inquiries encountered in travel consultations. The LLMs' initial responses were generated using the CDC’s Yellow Book as a foundational knowledge base. In the subsequent phase, the prompts were refined for greater specificity and clarity, and the knowledge base was enhanced by transitioning to Travax’s Travelers’ Health database. Additional structured data inputs included an exhaustive list of vaccines from our pharmacy formulary and a detailed table of vaccine contraindications. The responses were evaluated and scored by ID clinicians from the Mayo Clinic. Results Initial findings after first iteration revealed limited efficacy with recall at 23.9%, an F1 score of 38.6%, accuracy also at 23.9%, and precision maintained at 100%, utilizing the CDC's Yellow Book. With the implementation of Travax and refined prompting techniques, preliminary results suggest a notable improvement in the quality of responses, though detailed scoring is presently underway. Improvements in the LLM’s performance can be attributed to several key adjustments: the adoption of a more comprehensive knowledge base, refined prompt engineering, and the incorporation of structured data to support more accurate and detailed recommendations. The collaborative engagement of Mayo Clinic with Google and Travax facilitated a synergistic approach to optimizing the AI model's utility and integration. Future plans include embedding the LLM into our EMR system. Conclusion The findings from this study highlight the significance of strategic collaborations between large healthcare centers, IT industry, and specialized knowledge database firms in effectively harnessing GAI for clinical use. Disclosures All Authors: No reported disclosures
Refractory Psychosis as a Red Flag for End of Life in Individuals With Dementia With Lewy Bodies
Armstrong, Melissa J. , Manning, Carol A. , Taylor, Angela , Patel, Bhavana , Maixner, Susan M. , Armstrong, Melissa J , Galvin, James E. , Boeve, Bradley F. , Pontone, Gregory M. , Fleisher, Jori

Mayo Clinic

Alzheimer Disease & Associated Disorders | January 29, 2025 | Volume: 39 | Issue: 1 | Pages: 15-21

10.1097/wad.0000000000000660 | PMID 39878295 Get It

Objectives: Many individuals with dementia with Lewy bodies (DLB) die of disease-related complications, but predicting the end of life can be challenging. We identified a phenotype associated with approaching end of life. Methods: We present 4 exemplar cases where individuals with DLB experienced refractory psychosis before death. We reviewed codebooks and quotes from 3 studies regarding end-of-life experiences in DLB to identify experiences that aligned with this phenotype. Results: In addition to the 4 cases, family caregivers in prior studies described prominent worsening of psychosis before death in some individuals with DLB. The worsening often occurred several months before death and was sometimes associated with rapid deterioration. Worsening psychosis was the prominent symptom and was not initially accompanied by cognitive or physical decline. In many cases, the refractory psychosis resulted in inpatient psychiatric hospitalization or residential care, but these scenarios were challenging because of the individual’s behavior. Conclusion: Refractory psychosis in DLB, particularly out of proportion to other symptoms, may be a signal of approaching the end of life. More research is needed to understand this phenomenon and to develop effective and safe treatments for psychosis in DLB.
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials
Shi, Michael , Pungwe, Prisca , Comer, Lauren L., Balakrishnan, Maya , Lee, Tzu‐Hao , Cholankeril, George , Patidar, Kavish R. , Flores, Avegail , Shah, Vijay H. , Bataller, Ramón , Kanwal, Fasiha , Shi, Michael A , Comer, Lauren L M , Flores, Avegail G , Asrani, Sumeet K , Kanwal, Fasiha , Hernaez, Ruben , Bataller, Ramon A , Lee, Tzu-Hao , Patidar, Kavish R , Cholankeril, George , Asrani, Sumeet K. , Arab, Juan Pablo

Mayo Clinic

Hepatology | January 28, 2025 | Volume: 82 | Issue: 5 | Pages: 1241-1255

10.1097/hep.0000000000001237 | PMID 39874480 Get It

Background and Aims: Severe alcohol-associated hepatitis (AH) is rising in incidence with a high mortality burden. While corticosteroids are recommended for eligible patients with severe AH, no guidance exists for the timing of steroid initiation, tapering regimens, and surveillance of adverse events. We aim to systematically review these variables and provide evidence-based recommendations for the inpatient and outpatient management of severe AH. Approach and Results: We performed a literature search from inception to May 30, 2024, to include clinical trials published in full form and assessed the quality of evidence using the Cochrane Risk of Bias tool. Data were collected on the timing of initiation, rate, and complications following steroid therapy, and taper regimens in the setting of severe AH. Of 28 studies that fulfilled our inclusion criteria, the median time from admission to steroid initiation was 6.5 days. The most common steroid dosing regimen was prednisolone 40 mg daily for 28 days. Twenty-five studies containing 3196 subjects reported adverse events, with exactly 50% in the steroid arm and the other half in the comparison arm. Infections, gastrointestinal bleeds, and renal impairment were the most frequently reported adverse events. Most infections occurred within the first month of the study. A 2-week steroid taper was the most frequently reported regimen. Conclusions: We recommend taking up to a week to systematically and thoroughly evaluate patients before initiating steroids, and vigilant monitoring in the first month of treatment. We also recommend the lowest possible steroid exposure with a 2-week steroid taper and close outpatient follow-up.
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Dhakal, Binod , Lum, Lawrence G. , Glass, Deborah D, Park, Jee Hyun , Donato, Michele , Felizardo, Tania C., Fowler, Daniel H., Lum, Lawrence G , Dhakal, Binod , Hari, Parameswaran , Chhabra, Saurabh , Szabó, Anikó , Glass, Deborah D, Donato, Michele, Siegel, David S.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 28, 2025 | Volume: 13 | Issue: 1 | Pages: e010649

10.1136/jitc-2024-010649 | PMID 39875173 Get It

Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (TCM) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context. Methods The clinical trial (NCT04176380) evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma (RRMM). Results From December 2020 to December 2022, 14 patients with RRMM received a median of three RAPA-201 infusions (median dose, 80×106 cells). RAPA-201 drug products (DPs) were: polyclonal; enriched for TCM cells; reduced for immune checkpoint expression, including PD1, CD73, and LAIR1; and preferentially secreted Th1 cytokines. The median chemotherapy dose administered per cycle was 1,817 mg total for cyclophosphamide (range, 1,100–2,200) and 2.35 mg/M2 for pentostatin (range, 0–16). Nine of 14 patients (64%) achieved disease remission, with eight partial responses and one stringent complete response. Median progression-free survival was 6.0 months (range, 2.1 to>16.8 months). There were no toxicities of any grade attributable to RAPA-201, including no cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome. Only 4 of 14 patients (29%) had a serious adverse event (≥ grade 3) of any attribution. Conclusions Consistent with our hypothesis, ex vivo manufacturing using mTOR inhibition and IFN-α polarization consistently yielded a novel RAPA-201 DP that possessed a desirable phenotype relative to cytokine phenotype, memory status, and checkpoint expression. RAPA-201 recipients had preservation of T cell counts and Th1 cytokine secretion yet had increased T cell receptor clonality that associates with antitumor responses in the setting of monoclonal antibody checkpoint therapy. RAPA-201 therapy overcomes previous barriers to effective autologous polyclonal T-cell therapy, as it is feasible to manufacture, exquisitely safe to administer, and mediates remission in patients with RRMM. Trial registration number ClinicalTrials.gov: NCT04176380.
Clinical outcomes of patients with unsuccessful mechanical thrombectomy versus best medical management of medium vessel occlusion stroke in the middle cerebral artery territory
Faizy, Tobias D. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya A. , Musmar, Basel , Adeeb, Nimer , Essibayi, Muhammed Amir , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent , Gory, Benjamin, Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Valente, Iacopo , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Dmytriw, Adam A , Guenego, Adrien , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Siegler, James E. , Nguyen, Thanh N. , Möhlenbruch, Markus , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | January 23, 2025 | Volume: 18 | Issue: 1 | Pages: 155-165

10.1136/jnis-2024-022642 | PMID 39855674 Get It

Background Current randomized controlled trials are investigating the efficacy and safety of mechanical thrombectomy (MT) in patients with medium vessel occlusion (MeVO) stroke. Whether best medical management (MM) is more efficient than unsuccessful vessel recanalization during MT remains unknown. Methods This was a retrospective cohort study using data from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. Only patients with occlusion of the distal branches (M2 and M3) of the middle cerebral artery territory were included. Unsuccessful MT was defined as a modified Thrombolysis in Cerebral Infarction score of 0–2a. Propensity score matching was used to control for confounders. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after treatment. Multivariable regression analysis was used to assess factors associated with the primary outcome. Results Of 2903 patients screened for eligibility, 532 patients were analyzed (266 per group) after propensity score matching. The MM group had superior functional outcomes, with 32% achieving mRS 0–1 at 90 days compared with 21% in the MT group (P=0.011). Patients in the MM group also had significantly lower rates of symptomatic intracranial hemorrhage (sICH) (3.4% vs 16%, P<0.001) and any hemorrhage (18% vs 48%, P<0.001). On multivariable regression, unsuccessful MT was associated with reduced odds of functional independence (OR 0.50, 95% CI 0.29 to 0.85, P=0.011) and increased odds of sICH (OR 4.32, 95% CI 1.84 to 10.10, P<0.001). Mortality rates were similar between groups (27% in MM vs 29% in MT, P=0.73). Conclusion Unsuccessful MT for MeVO was linked to worse outcomes than best MM. These findings highlight the risks of prolonged attempts and emphasize the importance of efficient procedural decision-making to reduce complications and improve patient outcomes.
Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients With Cirrhosis: A Propensity-Matched Analysis of the US Collaborative Network
Beran, Azizullah , Elfert, Khaled , Patel, Feenalie N. , Mohamed, Mouhand , Ramai, Daryl , Canakis, Andrew , Thakkar, Shyam , Rex, Douglas K. , Bhavsar‐Burke, Indira , Guardiola, John , Guardiola, John J , Canakis, Andrew , Mohamed, Mouhand F H

Mayo Clinic

American Journal of Gastroenterology | January 16, 2025 | Volume: 120 | Issue: 11 | Pages: 2687-2691

10.14309/ajg.0000000000003322 | PMID 39950371 Get It

INTRODUCTION: Data on the risk of post-polypectomy bleeding after endoscopic mucosal resection (EMR) in patients with cirrhosis are limited. METHODS: This retrospective cohort study used the US Collaborative Network to assess post-polypectomy bleeding risk after colorectal EMR in patients with cirrhosis compared with controls. Using one-to-one propensity score matching, the primary outcome measured was bleeding within 30 days post-EMR. The bleeding risk was further stratified by cirrhosis severity (compensated and decompensated). RESULTS: After propensity score matching, each cohort included 2,381 patients. Patients with cirrhosis had a higher risk of post-polypectomy bleeding (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.05–1.82, P = 0.02). However, endoscopic reinterventions for hemostasis were similar between cirrhosis and control cohorts (OR 1.20, 95% CI 0.71–2.05, P = 0.50). The post-polypectomy bleeding risk was significantly higher in patients with decompensated cirrhosis (OR 1.65, 95% CI 1.12–2.42, P = 0.01), while those with compensated cirrhosis showed no increased risk of post-polypectomy bleeding (OR 1.15, 95% CI 0.85–1.54, P = 0.37). DISCUSSION: The post-polypectomy bleeding risk was higher in patients with decompensated cirrhosis, while the bleeding risk was not increased in those with compensated disease. Optimizing patients with cirrhosis, especially with decompensated disease, before colorectal EMR and monitoring for post-procedure bleeding remain important. A conservative, supportive approach to managing bleeding in patients with cirrhosis may be as effective as in those without cirrhosis.
Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.